Orforglipron
- Generic Name
- Orforglipron
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
- Conditions
- ObesityOverweightType 2 Diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT06972472
- Locations
- 🇺🇸
Southern California Clinical Research, Santa Ana, California, United States
🇺🇸Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson, Arizona, United States
🇺🇸Norcal Endocrinology & Internal Medicine, San Ramon, California, United States
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT06972459
- Locations
- 🇺🇸
Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson, Arizona, United States
🇺🇸Norcal Endocrinology & Internal Medicine, San Ramon, California, United States
🇺🇸Southern California Clinical Research, Santa Ana, California, United States
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 487
- Registration Number
- NCT06952530
- Locations
- 🇺🇸
Elite Clinical Studies, LLC, Phoenix, Arizona, United States
🇺🇸Valley Clinical Trials, Inc., Northridge, California, United States
🇺🇸Chase Medical Research, LLC, Waterbury, Connecticut, United States
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 974
- Registration Number
- NCT06948422
- Locations
- 🇺🇸
Elite Clinical Studies, LLC, Phoenix, Arizona, United States
🇺🇸Valley Clinical Trials, Inc., Northridge, California, United States
🇺🇸Chase Medical Research, LLC, Waterbury, Connecticut, United States
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
- Conditions
- HypertensionOverweight or Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 487
- Registration Number
- NCT06948435
- Locations
- 🇺🇸
Elite Clinical Studies, LLC, Phoenix, Arizona, United States
🇺🇸Valley Clinical Trials, Inc., Northridge, California, United States
🇺🇸Chase Medical Research, LLC, Waterbury, Connecticut, United States
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
- Conditions
- ObesityOverweight
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT06824051
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Axis, Dilworth, Minnesota, United States
🇺🇸Ohio Clinical Trials, Columbus, Ohio, United States
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 27
- Registration Number
- NCT06704763
- Locations
- 🇺🇸
ICON, Salt Lake City, Utah, United States
A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 80
- Registration Number
- NCT06692348
- Locations
- 🇯🇵
Sumida Hospital, Sumida-ku, Tokyo, Japan
🇯🇵Hakata Clinic, Fukuoka, Japan
🇯🇵Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 125
- Registration Number
- NCT06672939
- Locations
- 🇺🇸
Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Ventura, California, United States
🇺🇸Yale School of Medicine - Yale Diabetes Center (YDC)) Trials, New Haven, Connecticut, United States
🇺🇸Stamford Therapeutics Consortium, Stamford, Connecticut, United States
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 125
- Registration Number
- NCT06672549
- Locations
- 🇺🇸
Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Ventura, California, United States
🇺🇸Yale School of Medicine - Yale Diabetes Center (YDC)) Trials, New Haven, Connecticut, United States
🇺🇸Stamford Therapeutics Consortium, Stamford, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.